Self-Expanding Sinus Dilation Technology Offers More With Less
Executive Summary
SinuSys Corp. received FDA clearance in December 2013 for its Vent-Os Sinus Dilation System, a novel in-office treatment for patients with chronic rhinosinusitis (CRS) affecting the maxillary sinus that uses a self-expanding, removable capsule and osmotic technology to open the sinuses
You may also be interested in...
Lilly Looks To Take POINT On Emerging Cancer Radiopharmaceutical Space
Lilly has agreed to pay $1.4bn to acquire Point even though the company’s two lead candidates are out-licensed to Lantheus. The deal looks like an early-stage play to build a strong position in an emerging field.
Podcast: How Will Greater FTC Scrutiny Affect Biopharma M&A Activity?
Scrip’s Joseph Haas and Jessica Merrill discuss the US FTC’s oversight of the Amgen/Horizon deal and what it might portend for biopharma M&A with Leerink Partners' Dan Lepanto and ZS partner Cody Powers.
IVD DNA Test For Cancer Receives New Regulatory Classification
The approval for Invitae’s cancer risk diagnostic test opens the door for more tests of its kind.